Building a platform-driven pipeline

Illum is applying ConfoSeq to create carefully selected proprietary GPCR programs on validated targets.

Our objective is not simply to identify new compounds that activate or inhibit a receptor. It is to create medicines with pharmacological profiles designed for a specific therapeutic purpose.

Initial programs will be disclosed as they reach defined discovery milestones.